MERZ — Patent Portfolio
1 drug with active patents · 6 active patents · 0 expired · 0 biologics with BPCIA exclusivity
Verdict MERZ's pharmaceutical portfolio is moderately strong, with a significant cliff year in 2029 and no revenue at risk in the next 5 years.
Portfolio overview MERZ has a total of 1 drug with patents, out of 1 total drugs in their portfolio. The company has 6 active US patents and 0 expired US patents, with an average vulnerability score of 53. The portfolio consists of 0 ironclad patents and 2 vulnerable patents. There are no biologics in the portfolio.
Cliff calendar 1 drug loses exclusivity in 2029, including Inbrija. This marks a significant cliff year for the company. In 2029, 1 drug will lose exclusivity, posing a challenge to MERZ's revenue.
Most exposed drugs Inbrija is the top drug facing near-term loss of exclusivity, with an earliest active patent expiry date of 2029-02-03 and an average vulnerability score of 53. The annual revenue for Inbrija is not available.
Biologic exclusivity There are no biologics in the portfolio, meaning there is no BPCIA 12-year reference product exclusivity to consider.
Strategic implications With no revenue at risk in the next 5 years, MERZ has an opportunity to focus on lifecycle management strategies for Inbrija, such as subQ switches or label extensions, to maintain revenue. The company should consider combination filings to further extend the life of their patents.
Loss of exclusivity calendar · next 12 years
Drugs facing US patent or BPCIA biologic exclusivity loss per year. Click any year to see the broader cliff calendar for the industry.
Patent estate by drug
Inbrija (LEVODOPA)
Cliff 2029 · 3y-
USRE43711
Vuln 75
2029-02-03
This patent, US RE43711, protects a specific method of using the drug Inbrija.
-
US12458615
Vuln 75
2033-10-21
This patent protects methods for providing rapid relief of motor fluctuations in Parkinson's disease patients through the pulmonary administration of levodopa by inhalation.
-
US8545878
Vuln 42
2032-11-16
This patent protects a capsule containing a high-dose levodopa inhalable powder composition with specific ingredients and properties.
Patent classification breakdown · active patents
By US patent type. Method-of-use patents are most vulnerable to design-around; composition-of-matter patents are the strongest protection.
- Formulation 4 patents
- Method of Use 2 patents
Sources
- FDA Orange Book — small-molecule patents listed against approved NDAs.
- FDA Purple Book — biologic BPCIA 12-year reference product exclusivity.
- USPTO Patent Public Search — title, abstract, claim text grounding.
- AI summaries generated by Drug Landscape, grounded in source claim text.
Patent term extensions (PTR, SPC, pediatric exclusivity) may shift effective expiry. Not legal advice.
Track MERZ's patent estate
Daily alerts when vulnerability scores shift, patents expire, or IPRs are filed. Free tier: 3 watches. Pro tier (£199/mo): 50 watches + daily AI Pharma IP Brief.
↓ CSV export